Consensus Evotec SE

Stocks

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 03:35:27 31/10/26 am AEDT			5-day change	1st Jan Change
2.818 ^EUR	-3.82%		+0.28%	-48.29%

30/10	Evotec SE : RBC gives a Buy rating	ZD
30/10	RBC cuts target for Evotec to €5 - "Speculative Risk"	DP

Evolution of the Average Target: Evotec SE

Evolution of the Target Price: Evotec SE

Changes in Analyst Recommendations: Evotec SE

bd863d0c14670ffe41c137e20330a51.Xn8R9G92z7VShg0vRteAk_zCbNHcf80ZQPcyCYpCcws.GSpnljgTv9Jkz1tJFa_H58ixVLiqG5xuCKFQe71zK2ULL1jZPgCN4yPKVA~1b73d8bd7a3362eb3bbe15d1a489cd4c

Analysts' recommendations: Evotec SE

30/10	Evotec SE : RBC gives a Buy rating	ZD
30/10	RBC cuts target for Evotec to €5 - "Speculative Risk"	DP
16/10	Evotec SE : Berenberg reiterates its Neutral rating	ZD
15/10	Evotec SE : Gets a Neutral rating from Deutsche Bank	ZD
14/10	Evotec SE : RBC reaffirms its Buy rating	ZD
14/10	RBC leaves Evotec at 'Outperform' - price target 10 euros	DP
14/10	Evotec on recovery track with quarterly figures after 13-year low	DP
25/09	Evotec SE : Berenberg remains Neutral	ZD
19/09	Evotec at the top of the SDax - Positive comments at a conference	DP
13/08	Evotec SE : Gets a Buy rating from RBC	ZD
16/07	Berenberg Downgrades Evotec to Hold From Buy, Cuts Price Target to EUR3.60 From EUR9.40	MT
16/07	EVOTEC : Deutsche Bank reaffirms its Neutral rating	ZD
16/07	EVOTEC : Reduced to Neutral by Berenberg	ZD
16/07	Berenberg downgrades Evotec to 'Hold', target cut to €3.60	DP
16/07	Evotec Shares Fall After TD Cowen Downgrade	MT
15/07	TD Cowen Downgrades Evotec to Hold From Buy, Adjusts Price Target to $2 From $4	MT
14/07	EVOTEC : Deutsche Bank reaffirms its Neutral rating	ZD
14/07	EVOTEC : RBC gives a Buy rating	ZD
14/07	Evotec at risk of lowest share price in ten years after profit warning	DP
13/05	Evotec shares slide following convertible bond issue and equity placement	DP
08/05	EVOTEC : Deutsche Bank remains Neutral	ZD
07/05	EVOTEC : Deutsche Bank remains Neutral	ZD
06/05	EVOTEC : RBC remains its Buy rating	ZD
04/05	EVOTEC : RBC gives a Buy rating	ZD
20/04	EVOTEC : RBC reiterates its Buy rating	ZD

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EVOTEC SE					+57.66%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.41%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+31.75%
	Weighted average by Cap.					+27.06%